Postes actifs de Sebastian Inger
Sociétés | Poste | Début | Fin |
---|---|---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Sebastian Inger
Statistiques
Internationale
Danemark | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Health Technology |
- Bourse
- Insiders
- Sebastian Inger
- Expérience